George Siber M.D., Ph.D. — Chairman of Scientific Advisory Board and Executive Director at Genocea Biosciences

Dr. George R. Siber, MD, PhD serves as the Chief Scientific Officer of ClearPath Development Company and ClearPath Vaccines Company. Dr. Siber has been an Executive Director at Genocea Biosciences, Inc. since 2007. He served as an Executive Vice President of Wyeth Pharma. He served as the Chief Scientific Officer and Executive Vice President of Wyeth Vaccines, Ltd. He oversaw the development and approval of multiple widely-used childhood vaccines including an acellular pertussis vaccine (Acel-Imune), a meningococcal meningitis vaccine (Meningitec), and a pneumococcal vaccine (Prevnar). He served as an Associate Professor of Medicine at Dana Farber Cancer Institute. From 1970 to 1975, he went through intensive medical training in internal medicine and infectious diseases at Rush Medical Center in Chicago and Beth Israel and Children's Hospital at Harvard Medical School in Boston. He has extensive drug development experience and has been developing vaccines since his days in the public health service, a career of 35 years (post academic work). Additionally, while in Massachusetts, he led the research, the development and the approval of CytoGam(R) (CMV Immune Globulin) and RespiGam(R) (RSV Immune Globulin), both marketed by MedImmune. RespiGam(R) is the precursor product to Synagis(R), the first monoclonal antibody to an infectious disease. He serves as the Chairman of Scientific Advisory Board at Genocea Biosciences, Inc. He served as an Executive Chairman at Genocea Biosciences, Inc., from June 2007 to September 19, 2013. He serves as a Director of Affinivax, Inc. He serves as a Member of Scientific Advisory Board at Selecta Biosciences, Inc. He serves as a Member of the Scientific Advisory Board of Genocea Biosciences, Inc. He serves as a Member of Medical & Scientific Advisory Board at Veritas Genetics International Ltd. He has been a Member of Scientific Advisory Board at CureVac AG since March 30, 2016. He has been a Member of the Scientific Advisory Board of SynGlyco, Inc. since October 28, 2010. He served as a Member of the Supervisory Board at Crucell N.V. since June 2010. He has been a Trustee at International Vaccine Institute since November 18, 2013. He serves on numerous advisory committees including those of the PATH's Pneumococcal Vaccine Project, the Malaria Vaccine Initiative, the Gates Maternal Immunization Program, the Stop TB Task Force. He serves as a member of Scientific Advisory Board of several vaccine companies, including Novartis Vaccines and Diagnostics and Variation Biosciences. He serves on the Board of Scientific Counselors for the National Vaccine Center of the NIH and the Advisory Board of the Massachusetts Biologic Laboratories, University of Massachusetts Medical School. He served as a Director at Selecta Biosciences, Inc since 2009 until June 2016. He served as a Director of the Massachusetts Public Health Biologic Laboratories and Harvard Medical School. He served as a Member of Scientific Advisory Board of LigoCyte Pharmaceuticals, Inc. and Takeda Vaccines (Montana), Inc. He has served on numerous U.S. government and international advisory committees including the WHO/UNDP Steering Committee for Bacterial Vaccines, the Steering Committee for Development of Pneumococcal Vaccine for the Pan American Health Organization, the Institute of Medicine Committee on the Children's Vaccine Initiative and the NIH Blue Ribbon Panel for Bioterrorism and its Implications for Biomedical Research. He served as a Member of Scientific Advisory Board at Prothena Corporation plc. He has served on several US government and international advisory committees including the World Health Organization, the Pan American Health Organization, the Institute of Medicine and the Advisory Council of the National Institute of Allergy and Infectious Disease. He has authored more than 175 scientific articles and holds 4 patents. He served as the Chairman of the Scientific Review Committee of the U.S. Army's HIV research program in 2002 and 2006. He was named to the National Advisory Allergy and Infectious Diseases Council in 2010. Dr. Siber completed his Medical Degree at McGill University in Canada. He is also a Graduate of Bishop's University.